Biopharmaceutical Company Publishes Positive Data For Crohn's Disease Treatment

Newly Published Positive Phase 3 Data Demonstrates 64% Increased Efficacy with RedHill's RHB-104 in Crohn's Disease.

Disclaimer: The following article is for informational purposes only. It aims to present the findings of a clinical study and does not constitute medical advice. Always consult with a healthcare provider for medical advice, diagnosis, or treatment.

Real-time information is available daily at https://stockregion.net